Treatment | Overall | OMT | TEVAR | P value |
---|---|---|---|---|
N = 13 | N = 27 | |||
Age | 64.56 ± 9.93 | 66.23 ± 10.50 | 63.74 ± 9.74 | 0.44 |
Male gender | 36 (90.00%) | 11 (84.62%) | 25 (92.59%) | 0.43 |
Smoking | 8 (20.00%) | 3 (23.08%) | 5 (18.52%) | 0.74 |
Drinking | 3 (7.50%) | 1 (7.69%) | 2 (7.41%) | 0.97 |
Comorbidities | ||||
Hypertension | 28 (70.00%) | 8 (61.54%) | 20 (74.07%) | 0.47 |
Diabetes mellitus | 5 (12.50%) | 2 (15.39%) | 3 (11.11%) | 0.99 |
Coronary artery disease | 3 (7.50%) | 0 (0.00%) | 3 (11.11%) | 0.54 |
Stroke | 2 (5.00%) | 1 (7.69%) | 1 (3.70%) | 0.99 |
Malignant diseases | 0.53 | |||
Prostate cancer | 1 (2.50%) | 0 (0.00%) | 1 (3.70%) | |
Thyroid cancer | 3 (7.50%) | 0 (0.00%) | 3 (11.11%) | |
Lung cancer | 5 (12.50%) | 1 (7.69%) | 4 (14.82%) | |
Pancreatic cancer | 3 (7.50%) | 1 (7.69%) | 2 (7.41%) | |
Bladder cancer | 2 (5.00%) | 0 (0.00%) | 2 (7.41%) | |
Gastric cancer | 5 (12.50%) | 1 (7.69%) | 4 (14.82%) | |
Sarcoma | 2 (5.00%) | 1 (7.69%) | 1 (3.70%) | |
Nasopharyngeal carcinoma | 2 (5.00%) | 2 (15.39%) | 0 (0.00%) | |
Cholangiocarcinoma | 3 (7.50%) | 2 (15.39%) | 1 (3.70%) | |
Rectal cancer | 5 (12.50%) | 2 (15.39%) | 3 (11.11%) | |
Renal cancer | 5 (12.50%) | 2 (15.39%) | 3 (11.11%) | |
Liver cancer | 4 (10.00%) | 1 (7.69%) | 3 (11.11%) | |
Endstage of cancer | 4 (10.00%) | 2 (15.39%) | 2 (7.41%) | 0.58 |